Litcius/Paper detail

Biosafety in surgical pathology in the era of SARS-Cov2 pandemia. A statement of the Italian Society of Surgical Pathology and Cytology

Mattia Barbareschi

2020Pathologica25 citationsDOIOpen Access PDF

Abstract

Surgical pathology units face chemical and biological risks. While chemical risks have been intensely evaluated since the formalin ban, less attention has been drown to biological risks. The actual epidemiologic situation due to the SARS-CoV-2 pandemia has raised a series of questions, which need to be addressed as soon as possible. We have to pursue two lines of action: on one side we must immediately adopt urgent measures to reduce the risk of SARS-CoV-2 infection of our laboratory personnel, and on the other side we must address crucial technical and organizational aspects of biological risk reduction, preserving as much as possible the quality of tissue and cell samples. Continue reading (Download PDF)

Topics & Concepts

BiosafetyMedicineSurgical pathologyPathologyChemical pathologyCoronavirus disease 2019 (COVID-19)Intensive care medicineDiseaseInfectious disease (medical specialty)COVID-19 and healthcare impactsInfection Control and VentilationHealthcare and Environmental Waste Management
Biosafety in surgical pathology in the era of SARS-Cov2 pandemia. A statement of the Italian Society of Surgical Pathology and Cytology | Litcius